Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Detecting mitomycin C in human plasma during intravesical therapy.

K Jauhiainen

    International Urology and Nephrology
    |January 1, 1985
    PubMed
    Summary

    This study found no systemic absorption of Mitomycin C (MMC) in patients receiving intravesical instillation therapy, indicating low systemic toxicity. Significant MMC loss in urine suggests bladder wall absorption.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Current concepts in the role of intravesical instillations in the therapy and prophylaxis of superficial transitional-cell cancer of the bladder. The Finnbladder Research Group.

    World journal of urology·1997
    Same author

    Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finnbladder Group.

    The Journal of urology·1996
    Same author

    Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group.

    The Journal of urology·1995
    Same author

    Proliferation indices as independent prognostic factors in papillary Ta-T1 transitional cell bladder tumours.

    British journal of urology·1993
    Same author

    Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer.

    International journal of cancer·1993
    Same author

    Spontaneous peripelvic extravasation of urine as a cause of acute abdomen.

    Scandinavian journal of urology and nephrology·1993

    Area of Science:

    • Urology
    • Pharmacology
    • Oncology

    Background:

    • Intravesical Mitomycin C (MMC) is used for bladder cancer treatment.
    • Systemic toxicity is a concern with intravesical therapies.
    • Understanding MMC pharmacokinetics is crucial for safety and efficacy.

    Purpose of the Study:

    • To quantify Mitomycin C (MMC) concentrations in plasma and urine.
    • To assess systemic absorption and potential toxicity during intravesical instillation.
    • To investigate MMC disposition in patients with intact bladders.

    Main Methods:

    • Selective high-performance liquid chromatography (HPLC) was employed for precise MMC quantification.
    • Plasma and urine samples were collected from five patients undergoing intravesical MMC therapy.
    • A sensitive detection limit of 1 ng/ml was established for MMC analysis.

    Main Results:

    • No Mitomycin C (MMC) was detected in patient plasma samples.
    • The HPLC method demonstrated a detection limit of 1 ng/ml.
    • A significant reduction in MMC concentration was observed in voided urine.

    Conclusions:

    • Intravesical Mitomycin C (MMC) instillation therapy shows minimal systemic absorption in patients with intact bladders.
    • The observed lack of plasma MMC supports the clinical experience of low systemic toxicity.
    • Substantial urinary MMC loss suggests significant absorption into the bladder wall, warranting further investigation.

    Related Experiment Videos